Managing Small Airway Disease in Patients with Severe Asthma: Transitioning from the “Silent Zone” to Achieving “Quiet Asthma”
Journal of Clinical Medicine · 17.04.2024 · 13 (8) · 2320
DOI: 10.3390/jcm13082320 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 17.04.2024. Verfasst von Giovanna Elisiana Carpagnano und 8 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Diseases, University of Bari, 70121 Bari, Italy. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Several studies have demonstrated the positive clinical and functional impact of adding Long-Acting Muscarinic Antagonist (LAMA) to Inhaled Corticosteroids (ICS) and Long-Acting Beta-Agonists (LABA) therapy in the treatment of severe asthma. Aim and objectives: To demonstrate that treating Small Airways Disease (SAD) in severe asthma patients who are candidates for biologics can improve respiratory symptoms, lung function, and airways inflammation, potentially avoiding or delaying the use of biological therapy.
Methods
Thirty-two severe asthma patients with SAD were transitioned from separate inhalers for ICS/LABA and LAMA to extrafine single-inhaler beclomethasone, formoterol, and glycopyrronium. None of these patients underwent biological therapy before the study. Follow-up evaluations were conducted at baseline (T0) and three months after initiation (T3). Assessments included clinical evaluations, spirometry, oscillometry, and inflammation markers.
Results
Transitioning to single-inhaler triple therapy from T0 to T3 resulted in significant improvements in Asthma Control Test (ACT) and SAD parameters, including increased Forced Expiratory Volume in the mid-range of lung capacity and improved airway resistance and reactance measurements using impulse oscillometry. A significant reduction in airway inflammation was evidenced by lower levels of Fractional Exhaled Nitric Oxide 350 (FeNO 350) (p < 0.001 for all).
Conclusions
Adopting a single-inhaler triple therapy notably enhanced clinical control and small airway function in patients with severe asthma and SAD, supporting the positive impact of target-therapy for the achievement of a stable state termed “Quiet Asthma”.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Respiratory Diseases, University of Bari, 70121 Bari, Italy.
ORCID-Profile: Andrea Portacci, Silvano Dragonieri, Vitaliano Nicola Quaranta
Zitieren
APA
Carpagnano, G. E., Portacci, A., Dragonieri, S., Montagnolo, F., Iorillo, I., Lulaj, E., Maselli, L., Buonamico, E., & Quaranta, V. N. (2024). Managing Small Airway Disease in Patients with Severe Asthma: Transitioning from the “Silent Zone” to Achieving “Quiet Asthma”. Journal of Clinical Medicine, 13(8), 2320. https://doi.org/10.3390/jcm13082320
Vancouver
Carpagnano GE, Portacci A, Dragonieri S, Montagnolo F, Iorillo I, Lulaj E, et al. Managing Small Airway Disease in Patients with Severe Asthma: Transitioning from the “Silent Zone” to Achieving “Quiet Asthma”. Journal of Clinical Medicine. 2024;13(8):2320. doi:10.3390/jcm13082320
BibTeX
@article{Carpagnano2024,
author = {Carpagnano, Giovanna Elisiana and Portacci, Andrea and Dragonieri, Silvano and Montagnolo, Francesca and Iorillo, Ilaria and Lulaj, Ernesto and Maselli, Leonardo and Buonamico, Enrico and Quaranta, Vitaliano Nicola},
title = {Managing Small Airway Disease in Patients with Severe Asthma: Transitioning from the “Silent Zone” to Achieving “Quiet Asthma”},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {8},
pages = {2320},
doi = {10.3390/jcm13082320}
}
EUVIMED